Genomic Landscape in Prostate Cancer in a Latin American Population

Martín Angel ^1,2, Berenice Freile ^1,2, Andres Rodriguez ^1,2

¹Instituto Alexander Fleming, Buenos Aires, Argentina.
²FUCA, Buenos Aires, Argentina.
³Hospital Italiano de Buenos Aires, CABA, Argentina.
⁴Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia.
⁵Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú.
⁶Instituto Nacional De Cancerología (Colombia), Bogotá, Colombia.
⁷Centro Oncológico Integral, Neuquén, Argentina.
⁸Clínica Las Américas Medellín, Antioquia, Colombia.
⁹Hospital Militar Central, Buenos Aires, Argentina.
¹⁰Hospital Universitario Austral, Buenos Aires, Argentina.
¹¹Instituto Misionero del Cáncer, Misiones, Argentina.
¹²Instituto del Cáncer Red Salud, Santiago de Chile, Chile.
¹³Hospital Centro de Salud Zenón Santillán, Tucumán, Argentina.
¹⁴Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.

⁰Instituto Alexander Fleming, Buenos Aires, Argentina.

Jco Global Oncology +

|

September 30, 2024

View abstract on PubMed

Summary

Genomic profiling of metastatic prostate cancer (mPC) patients reveals insights into tumor mutations. This study highlights the genomic landscape in Latin America, informing real-world treatment strategies.

Area Of Science

Oncology
Genomics
Prostate Cancer Research

Background

Metastatic prostate cancer (mPC) presents diverse genomic alterations.
Understanding the genomic profile of mPC is crucial for targeted therapy selection.
Latin America (LATAM) has limited representation in large-scale prostate cancer genomic studies.

Purpose Of The Study

To characterize the genomic alterations in a cohort of patients with metastatic prostate cancer (mPC).
To describe the genomic testing landscape in mPC patients within academic centers.
To contribute to the understanding of advanced prostate cancer genomics in LATAM.

Main Methods

Retrospective, multicenter cohort study including 349 patients with prostate cancer (PC).
Genomic analysis performed using multigene panel testing and next-generation sequencing (NGS) of BRCA1/BRCA2.
Data collected from 12 academic centers across five countries, with a focus on Latin America.

Main Results

Genomic analysis was performed in 233 patients with metastatic castration-resistant prostate cancer (mCRPC) and 115 with metastatic hormone-sensitive prostate cancer.
BRCA1/BRCA2 mutations were assessed in 59 patients; 2 out of 6 patients with BRCA mutations received PARP inhibitors.
Progression-free survival (PFS) in the mCRPC subgroup was not reached at 16 months for patients with BRCA mutations, versus 26.3 months for those without.

Conclusions

This study represents one of the largest datasets for somatic testing in prostate cancer patients in Latin America.
The findings provide valuable real-world data on the genomic landscape of advanced prostate cancer in LATAM.
This research enhances the understanding of genomic characteristics in a population often underrepresented in clinical trials.